
BTSG Stock Forecast & Price Target
BTSG Analyst Ratings
Bulls say
BrightSpring Health Services Inc. has demonstrated robust performance, particularly in its OP Rehab and Pharmacy Solutions segments, with Specialty revenue reaching approximately $2.6 billion in 2025, reflecting a 43% year-over-year growth and an improved EBITDA margin. The strategic acquisition of Amedisys and LHC has enhanced the Provider division's geographic reach, contributing to a 15% year-over-year increase in home health average daily census in 4Q:25, while stable reimbursement trends support continued growth. Furthermore, BrightSpring's focus on leveraging specialty drug spend, projected to grow at a compound annual growth rate of 10%-15%, positions the company favorably within its market, fostering the potential for increased generic drug market share and significant EBITDA enhancement in the years ahead.
Bears say
The financial outlook for BrightSpring Health Services Inc. is negatively impacted by potential weakening in client budgets, which could adversely affect business and revenue generation, particularly within its Pharmacy Solutions segment. Additionally, the company faces risks related to reduced prescription writing by healthcare professionals and diminished drug utilization, both of which could negatively impact revenues, operating results, and cash flows. Furthermore, the significant debt burden may constrain BrightSpring Health's ability to invest in growth initiatives, limiting potential expansion opportunities despite the acquisition of additional home health locations.
This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.
BTSG Analyst Forecast & Price Prediction
Start investing in BTSG
Order type
Buy in
Order amount
Est. shares
0 shares